secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0001453687-25-000091
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics enrolls first patient in Phase 3 AURORA trial of Descartes-08 for myasthenia gravis
--------------------------------------------------------------------------------

- First participant enrolled in randomized, placebo-controlled Phase 3 AURORA trial of Descartes-08 (CAR-T) in ~100 patients with AChR Ab+ myasthenia gravis.
- Descartes-08 is administered outpatient without preconditioning chemotherapy; primary endpoint is proportion with MG-ADL improvement ≥3 points at Month 4.
- Phase 2b data cited: average 4.8-point MG-ADL reduction at Month 12; in biologic-naive subgroup 7.1-point reduction and 57% minimal symptom expression.
- Safety profile consistent with prior data; continues to support outpatient administration without integrating vectors or conditioning chemotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000091/0001453687-25-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000091/rnac-20250530.htm
  HTML page:      https://secwatch.observer/filing/0001453687-25-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer